openPR Logo
Press release

ORGANOBALANCE Signs Licensing Agreement with Sanofi Pasteur

01-12-2012 07:52 AM CET | Health & Medicine

Press release from: ORGANOBALANCE GmbH

/ PR Agency: COMAGO Kommunikation . Marketing . Organisation
Modified strain of yeast paves way for new industrial vaccine production process

Berlin, 11 January 2012 – The company ORGANOBALANCE GmbH, Berlin, Germany, today announced the conclusion of a licensing agreement with Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY). This will provide Sanofi Pasteur with access to a modified yeast strain (Saccharomyces cerevisiae, more commonly known as baker's yeast) for use in vaccines. By signing the agreement, ORGANOBALANCE is granting Sanofi Pasteur exclusive rights to use of the modified yeast strain in the production of vaccines.

Prof. Christine Lang, Managing Director of ORGANOBALANCE GmbH, sees the licensing agreement as a further milestone for the company: "The modified form of Saccharomyces cerevisiae, both developed and patented by our company, is just one example of the far-reaching expertise ORGANOBALANCE has to offer in the field of metabolic engineering. By making this agreement, we are strengthening our outstanding position in microbial strain development and the application of yeasts in industrial biotechnology. We are delighted to have made this agreement with Sanofi Pasteur, a partner who will make commercial use of our research findings on an industrial scale."

ORGANOBALANCE GmbH is a company specialising in microbiological strain development. ORGANOBALANCE targets the use of Saccharomyces cerevisiae yeast strains for synthesising materials which can be applied in the processes of industrial and pharmaceutical biotechnology. The company also focuses on tapping the potential of beneficial microorganisms, known as specific probiotic cultures, in order to balance out the microflora and restore the microbial equilibrium in a natural way. By drawing on its own collection of microorganisms suitable for use in foodstuffs, as well as its own OASSYS® screening systems, ORGANOBALANCE develops new biological products in the areas of pharmaceutics, preventive healthcare, nutrition and cosmetics. ORGANOBALANCE was founded in 2001 and is based in Berlin, Germany. More information can be found at http://www.organobalance.com.

Further information:
ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin
Germany
Tel.: +49 30 46307-200
Fax: +49 30 46307-210
Email: info@organobalance.com
Internet: http://www.organobalance.com

Press contact:
COMAGO
Communication . Marketing . Organisation
Helmut Landenberger
Wiesenstraße 55
14612 Falkensee
Germany
Tel.: +49 33 22 84 06 52
Fax: +49 33 22 84 06 53
Email: mail@comago.de
Internet: http://www.comago.de

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ORGANOBALANCE Signs Licensing Agreement with Sanofi Pasteur here

News-ID: 206785 • Views:

More Releases from ORGANOBALANCE GmbH

Increasing the Potential for Yeast Strains in Biotech Manufacturing
ORGANOBALANCE to present its latest research findings at ACHEMA 2012 Berlin, 13 June 2012 – At this year's ACHEMA (Frankfurt,18 to 22 June), the Berlin-based biotech company ORGANOBALANCE GmbH will present its most recent findings on the potential uses of yeast strains in the biotechnological production of fine chemicals and new ingredients for pharmaceuticals, cosmetics, foods or feedstuffs (metabolic engineering of yeasts). In his talk, The yeast Saccharomyces cerevisiae as platform organism
Lonza and ORGANOBALANCE Enter Global License Agreement to Develop and Market Uni …
Basel, Switzerland and Berlin, Germany, 19 April 2011 – Lonza and ORGANOBALANCE today announced the signing of a worldwide exclusive license agreement in which Lonza will develop, produce and commercialize products containing a probiotic Lactobacillus strain. Developed by ORGANOBALANCE GmbH, the probiotic strain acts against Helicobacter pylori (H. pylori). Research shows that H. pylori has been implicated as a common cause of peptic ulcers and gastritis. Currently, about 50 percent of
ORGANOBALANCE to present latest research findings at the BIOTECHNICA Trade Show …
Berlin-based company to intensify efforts in contract research and white biotechnology Berlin, September 28, 2010 – Once again this year, ORGANOBALANCE will present current projects and latest research findings to an international audience of experts at the BIOTECHNICA Trade Show taking place in Hannover, Germany from October 5 to 7, 2010. Since 2001, the Berlin-based company has been doing research - primarily for clients from the fields of red, white and green
ORGANOBALANCE Announces Substantial Investment
Dr Bernd Wegener to invest in Berlin (Germany) Biotech company Berlin (Germany), 17 June 2010 – ORGANOBALANCE GmbH Berlin and Bernd Wegener DVM, PhD (Chairman of the Board of the German Federal Association of the Pharmaceutical Industry), have announced the completion of an investment agreement which shall take immediate effect. Aside from detailing a financial commitment, the agreement also foresees an active role for Dr Wegener in a position of responsibility

All 5 Releases


More Releases for Sanofi

Prostate Cancer Market 2032 Astellas, AstraZeneca plc, Johnson & Johnson, Sanofi …
The global prostate cancer market is poised to grow at an exponential pace, primarily due to the mounting prevalence of prostate cancer, rapidly aging population and strong bolstering pipeline. The market would undergo a transformation during the analysis period, attributed by emerging product launches and line extensions opted for existing therapies. Limited treatment options along with a booming patient pool has generated the need for novel effective therapies with enhanced
Therapeutic BCG Vaccines market: Key Market Developments and Innovations in 2022 …
" The Therapeutic BCG Vaccines global market is thoroughly researched in this report, noting important aspects like market competition, global and regional growth, market segmentation and market structure. The report author analysts have estimated the size of the global market in terms of value and volume using the latest research tools and techniques. The report also includes estimates for market share, revenue, production, consumption, gross profit margin, CAGR, and other key
Vaccine Market 2021 Analysis by Global Manufacturers - GlaxoSmithKline plc, Merc …
The Vaccine Market report offers an in-depth assessment of market dynamics, the competitive landscape, segments, and regions in order to help readers to become familiar with the Vaccine market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to plan effective strategies for gaining successful in the Vaccine market. Importantly, it allows players to gain deep insights into the business development
Travelers Vaccines Market 2027: Top Players & COVID-19 Impact Analysis - Merck , …
Travelers Vaccines Market Reports presents an in-depth assessment of this report including market drivers, challenges, enabling technologies, vertical market opportunities, applications, key trends, standardization, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report mainly studies the size, recent trends and development status of the Travelers Vaccines market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement
Global Freeze-Dried BCG Vaccine Market 2020 - Merck, Sanofi Pasteur (Sanofi), Ja …
Goble Freeze-Dried BCG Vaccine Market 2020, Market Size Value CAGR (USD Million)and revenue ($$$) for the historical period (2016 - 19) and projected years (2020 - 26), SWOT, Industry, Sales, Demand, Analysis, Opportunities and Forecast to 2026 All Cover in This Report Freeze-Dried BCG Vaccine View Detailed Report at @ http://www.marketresearchstore.com/report/global-freeze-dried-bcg-vaccine-market-professional-survey-618056 Market study on most trending report Global global Freeze-Dried BCG Vaccine Market 2020 Industry Research Report detailed information on
Immense Growth In Isoproterenol Market Trends and Global Overview | Sanofi Avent …
The 'Global Isoproterenol Industry, 2014-2024 Market Research Report' is a professional and in-depth study on the current state of the Global Isoproterenol Market with a focus on the market conditions. The report provides key statistics on the market status of the Isoproterenol manufacturer and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry